Author:
Ibáñez Vodnizza Sebastián,Martínez Oriela,Valenzuela Francisca
Abstract
Na artrite psoriática e na espondiloartrite, ainda há espaço para novos fármacos, com diferentes mecanismos de ação, que permitam melhor personalização do tratamento. O objetivo desta revisão é facilitar a decisão do clínico de usar tofacitinibe, upadacitinibe ou guselkumabe, novas alternativas de tratamento dentro da ampla variedade de medicamentos disponíveis atualmente
Publisher
Pan American League of Associations of Rheumatology (PANLAR)
Reference59 articles.
1. Poddubnyy D, Sieper J. Current Unmet Needs in Spondyloarthritis. Curr Rheumatol Rep. 2019 Jul 13;21(9):43.
2. Deodhar A, Strand V, Conaghan PG, Sullivan E, Blackburn S, Tian H, et al. Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study. BMC Rheumatol. 2020;4:19.
3. PubChem. Upadacitinib [Internet]. [cited 2021 Dec 8]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/58557659
4. McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1;384(13):1227–39.
5. Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Trial [Internet]. ACR Meeting Abstracts. [cited 2021 Oct 11]. Available from: https://acrabstracts.org/abstract/association-between-clinically-meaningful-improvements-in-patient-reported-outcomes-and-stringent-measures-of-disease-activity-in-patients-with-psoriatic-arthritis-treated-with-upadacitinib-versus-pla/